Majestec-9, in post-Darzalex multiple myeloma, is the latest success.

JNJ-95566692 enters phase 1, with Qilu neck and neck.

Three private biotechs enter clinical trials, one targeting KRAS.

But PFS data are lacking, and there are questions about first and second-line plans.

But the company still has a lot to prove with ERAS-0015.

The company will start three phase 3 trials of its G12D project this year.